Fort Worth, TX (PRWEB) July 14, 2011
The Center for Cancer & Blood Disorders is partnering with Sarah Cannon Research Institute (SCRI) to increase cancer treatment options in Fort Worth and across north Texas, through dozens of active clinical trials, http://www.thecentertx.com/clinical_trials.html.
Ray Page, D.O., Ph.D., President and Director of Research for The Center for Cancer and Blood Disorders, http://www.thecentertx.com/physicians_page.html, said, “SCRI is among the largest research programs in the nation. This means cancer treatment in Fort Worth is accelerating—offering many more options for patients through promising new drugs or the best available conventional treatment. If a new option is proven to work, these patients will be among the first to benefit. While there is no guarantee that any research will be successful, clinical trials offer some of the most effective cancer treatment available today.”
Access to more clinical trials also means Fort Worth and north Texas cancer patients can receive advanced care in a familiar location, close to home. This type of treatment is often offered only at major academic research sites.
SCRI clinical trial participation is available at these locations of The Center for Cancer & Blood Disorders: Fort Worth – Central Campus, Fort Worth – N. Medical Center, Fort Worth – Southwest, Arlington, Burleson, Weatherford, Mineral Wells, Cleburne, Granbury, and Stephenville.
The Center for Cancer & Blood Disorders, http://www.thecentertx.com, offers world-class cancer treatment to more than 6,000 patients annually at ten locations.